{
    "url_original": "https://www.wsj.com/articles/biotech-ipos-slow-after-record-breaking-2021-11645700402?mod=markets_lead_pos13",
    "url": "biotech-ipos-slow-after-record-breaking-2021-11645700402",
    "title": "Biotech IPOs Slow After Record-Breaking 2021",
    "sub_head": "Investors say industry’s fundamentals remain strong",
    "category_1": "Pro VC Industry News",
    "image_1_url": "https://images.wsj.net/im-491683?width=860&height=573",
    "image_1": "im-491683.jpg",
    "time": "2022-02-24 06:00:00",
    "body": "Initial public offerings by biotechnology companies are slowing after two record-setting years as the poor performance of some recent IPOs combined with economic and geopolitical uncertainties have cooled interest in the sector.<br />Seven biotech companies have gone public in the U.S. this year as of Feb. 22, compared with 21 as of the same date in 2021, according to data from Nasdaq, the exchange that hosted nearly all of those stock-market debuts."
}